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ABSTRACT
Objective: A variety of pharmacologic therapies are avail-
able or in development for the prevention of breast cancer
recurrence. Assessing the value of these treatments is com-
promised by a paucity of data on the impact of recurrence on
economic costs and survival. The purpose of this study was to
shed light on these issues.
Methods: We conducted a retrospective analysis of linked
SEER-Medicare data. All patients in the National Cancer
Institute’s Surveillance Epidemiology and End Results
(SEER) registry who were diagnosed with nonmetastatic
breast cancer during 1991–1993 were identiﬁed, and their
subsequent Medicare claims were scanned for evidence of
further breast cancer events (local or distant recurrence, con-
tralateral breast cancer). Medicare claims were then scanned
from the time of the event through 2002 to assess patterns of
survival and costs.
Results: We identiﬁed 10,798 patients in SEER who were
diagnosed with nonmetastatic breast cancer during 1991–
1993, including 1833 who subsequently had another breast
cancer event (local recurrence, 958; distant recurrence, 622;
contralateral breast cancer, 253). Median survival was
37 months and 8 months among patients with local and
distant recurrence, respectively; 53% of patients with con-
tralateral breast cancer remained alive after all the data were
censored at 97 months. Expected 10-year costs (2004 US$,
discounted 3%) attributable to distant recurrence, local
recurrence, and contralateral breast cancer were $11,450
(SE 2056), $19,596 (SE 1754), and $19,183 (SE 4131),
respectively.
Conclusion: Breast cancer recurrence and contralateral
breast cancer lead to substantial increases in costs, amount-
ing to approximately $11,000–19,000 over 10 years depend-
ing on type. The impact of these events on survival also varies
considerably by type.
Keywords: breast cancer recurrence, costs, Kaplan–Meier
Sample Average estimator, SEER-Medicare, survival.
Introduction
Breast cancer is the most common form of cancer
diagnosed among women in the United States, with
approximately 270,000 new cases forecast for the year
2005 [1]. Overall breast cancer mortality declined
2.3% annually between 1990 and 2001 because of
advances in awareness, detection, and treatment [1];
however, the risks of recurrence and new cancers in the
contralateral breast remain high and may result in
increased morbidity and mortality, particularly if the
cancer becomes more invasive. The 5-year survival rate
for localized cancer is 98% compared to only 25% for
distant metastases [1].
The risk of recurrence for patients with breast
cancer has been reported to peak within the ﬁrst
5 years after primary treatment [2]. In one study,
approximately 45% of the patient population experi-
enced a recurrence over the course of 12 years of
follow-up [2]. More recently, a retrospective analysis
of early-stage breast cancer patients who were disease-
free 5 years after diagnosis reported 15-year risks of
recurrence for stage II and stage III tumors to be 21%
and 30%, respectively [3].
A variety of pharmacologic therapies are available
or in development for the prevention of breast cancer
recurrence. Until recently, tamoxifen had been the
mainstay of adjuvant breast cancer treatment, but the
aromatase inhibitors have been found to decrease risks
of local and distant recurrence as well as contralateral
breast cancer, and are increasingly being used in this
indication [4,5]. In addition, trastuzumab has now
been shown to be effective in women with HER-2
positive nonmetastatic breast cancer [6]. Assessing the
economic beneﬁts of these treatments requires balanc-
ing their added costs against future cost-savings they
may bring about as a consequence of reduced inci-
dence of breast cancer-related events. Longitudinal
data on the costs of treating breast cancer recurrence
and new contralateral breast cancers are limited,
Address correspondence to: David Thompson, i3 Innovus, 10
Cabot Road, Suite 304, Medford, MA 02155 USA. E-mail:
david.thompson@i3innovus.com
10.1111/j.1524-4733.2007.00226.x
Volume 11 • Number 2 • 2008
V A L U E I N H E A LT H
© 2008, International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 1098-3015/08/213 213–220 213
however. The purpose of this study was to address this
issue using SEER-Medicare data.
Methods
Data Source
The National Cancer Institute’s Surveillance Epidemi-
ology and End Results (SEER) registry is a cancer
reporting system with databases that include infor-
mation on cancer incidence and survival from 11
population-based and three supplemental cancer reg-
istries covering approximately 14% of the US popula-
tion [7]. Data include detailed clinical, demographic,
and cause of death information for persons diagnosed
with incident cancer who reside in one of the geo-
graphic areas participating in the SEER program.
Clinical data include up to 10 cancer-related diagnoses
including the primary site and histology and tumor
stage at diagnosis for each patient.
The SEER-Medicare linkage combines the cancer
registry data with administrative Medicare ﬁles from
the Centers for Medicare and Medicaid Services. The
Medicare ﬁles contain health-care utilization and cost
information for hospital inpatient and outpatient care,
physician and other professional services, home health
services, as well as hospice and skilled nursing facility
utilization. At the time of conduct of this study, Medi-
care claims data were available from calendar years
1991 through 2002.
Sample Selection
All patients aged 65 years and older with a diagnosis
of nonmetastatic breast cancer (cancer site labeled
“breast” and stage-coded as I, II, or III in SEER)
between January 1, 1991 and December 31, 1993
were identiﬁed in the SEER-Medicare database. In
order to avoid misclassiﬁcation of the type of breast
cancer event (local or distant recurrence, contralateral
breast cancer), we selected for analysis only patients
who did not have a history of other malignancies
before the diagnosis of breast cancer. Additionally,
patients were selected only if the stage of their cancer
was known at the time of diagnosis; patients with
American Joint Committee on Cancer stage 0 breast
cancers were also excluded. Several additional exclu-
sion criteria were implemented to ensure completeness
of the follow-up data, including absence of Medicare
coverage throughout the study period, enrollment in a
Medicare HMO at any time during the study period,
and Medicare eligibility based on disability or end-
stage renal disease. We also excluded patients whose
initial diagnosis was made at the time of death or
autopsy because no follow-up care could have been
provided. Finally, we excluded patients for whom the
end of initial breast cancer treatment could not be
determined based on Medicare claims; this was neces-
sary to permit identiﬁcation of subsequent breast
cancer treatment.
All patients meeting the sample selection criteria
were included in the analysis of breast cancer events. In
addition, data on patient demographics (age, race, geo-
graphic region, median household income) and clinical
status (primary cancer treatment, year of initial diag-
nosis, estrogen receptor status) were obtained from
records in SEER. Median household income was deter-
mined from merged census data.
Identiﬁcation of Breast Cancer Events
Breast cancer events include local and distant breast
cancer recurrence as well as contralateral breast cancer
occurring subsequent to the initial primary breast
cancer diagnosis recorded in SEER. Local and distant
breast cancer recurrences were identiﬁed using an
approach similar to one proposed by Earle et al. [8].
Patients were followed through their initial treatment
of breast cancer by scanning claims for treatment with
mastectomy, chemotherapy, and/or radiotherapy. Such
care was identiﬁed using the International Classiﬁca-
tion of Diseases 9th Revision, Clinical Modiﬁcation
(ICD-9-CM), Healthcare Common Procedure Coding
System/Current Procedural Terminology (HCPCS/
CPT), and Diagnosis-Related Groups (DRG) coding
systems (Table 1). The occurrence of any one of these
types of treatment within a period of 30 days prior
or 90 days subsequent to the date of breast cancer
diagnosis, as recorded in SEER, was used to identify
Table 1 Codes for identifying types of cancer treatment
Type of treatment ICD-9-CM diagnosis ICD-9-CM procedure HCPCS/CPT DRG
Mastectomy 85.41–85.48,
85.21–85.22
19,160–19,240 257–260
Chemotherapy V58.1 99.25 Q0083–Q0085,
Q0164–Q0168,
J8510–J8999,
J9000–J9999,
96400–96450,
96452–96545
410
Radiotherapy V58.0 92.21–92.29 77,401–77,417 409
DRG, Diagnosis-Related Groups; HCPCS/CPT, Healthcare Common Procedure Coding System/Current Procedural Terminology; ICD-9-CM, International Classiﬁcation of
Diseases 9th Revision, Clinical Modiﬁcation.
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the period of primary breast cancer treatment. When a
gap in treatment of at least 90 days after primary
treatment was encountered, it was assumed that the
primary treatment episode had ended; if treatment was
later restarted more than 90 days after the end of
initial treatment, it was taken to indicate recurrent
breast cancer. Because SEER does not include informa-
tion on cancer recurrence, the type of recurrence was
inferred from the ﬁrst-listed ICD-9-CM diagnosis code
recorded on Medicare billing claims. Diagnosis codes
indicating a secondary cancer in the breast (198.81 or
198.2) or lymph node (196.xx) were used to classify
the recurrence as local. Distant recurrence was identi-
ﬁed either by ICD-9-CM diagnosis codes for secondary
cancers (197.xx-198.xx) excluding breast (198.81,
198.2) and lymph node (196.xx), or by death from
cancer within 60 days of recurrence.
Contralateral breast cancer was identiﬁed from
SEER data based on subsequent cancers in the breast
in which the laterality was opposite to the one
affected by the patient’s initial cancer. If the combi-
nation of a patient’s claims history and clinical
history from SEER met criteria for more than one
type of recurrence, we classiﬁed it hierarchically as
distant, contralateral, or local. This hierarchy was
used since claims for the treatment of contralateral
primary cancers in SEER were likely to be coded as
local secondary cancers on Medicare claims. Since
there are no existing ICD-9-CM diagnosis codes indi-
cating contralateral primary cancer, whenever local
recurrence was detected in the Medicare claims, con-
tralateral breast cancer was ruled out by also check-
ing the patient’s clinical history in SEER. If
contralateral breast cancer was not recorded in SEER,
it was assumed that the recurrence type was local.
Additionally, it was not uncommon to ﬁnd claims
indicating local recurrence before the observation of
ICD-9-CM diagnosis codes indicating distant recur-
rence in the same treatment episode.
It should be noted that the approach used for iden-
tifying cancer recurrence was based on a study exam-
ining recurrence of acute myelogenous leukemia [8]. It
is not known if the high speciﬁcity and sensitivity
reported in that study are analogous to solid tumors
such as breast cancer. Furthermore, ICD-9-CM diag-
nosis codes were used to measure cancer stage and
then classify the type of recurrence. A study by Cooper
et al. concluded that using the diagnostic coding
within Medicare claims to measure stage is subject to
misclassiﬁcation bias [9]. Nevertheless, Cooper et al.
examined new primary cancers and it is unknown if
the same misclassiﬁcation issues exist for detecting
local or distant breast cancer recurrence. Another
study examining the accuracy of the Medicare claims
in identifying breast cancer relapse concluded that the
use of ICD-9-CM codes for “secondary malignant neo-
plasm” excluding “secondary malignant neoplasm
of unspeciﬁed site” correctly categorized relapsed
patients with a sensitivity of 92% and a speciﬁcity of
94%, respectively [10].
Estimation of Survival after Breast Cancer Event
Survival analyses using the product-limit (Kaplan–
Meier) formula were used to estimate life expectancy
following local or distant recurrence or contralateral
breast cancer. The time to death was calculated as the
number of months from the date of diagnosis of the
breast cancer event (recurrence or contralateral breast
cancer) to the date of death, as recorded in SEER.
Patients whose follow-up times ended before their
deaths were censored at the end of their follow-up
period.
Estimation of Medical-Care Costs
To estimate costs of recurrence and contralateral
breast cancer, the period of follow-up was divided into
pre-event and postevent periods. The term “event”
refers to either the breast cancer recurrence or con-
tralateral breast cancer occurring after the initial
primary breast cancer diagnosis recorded in SEER. The
pre-event period was assumed to begin 91 days after
the end of initial treatment; this was done to ensure
that subsequent cancer care was for a breast cancer
event rather than a continuation of initial treatment.
We assumed health-care utilization 90 days before a
breast cancer event actually reﬂected the experience of
patients with, rather than without, recurrent disease.
Therefore, the postevent period was deﬁned to begin
90 days before the event, and the pre-event period
deﬁned to end the day before. Patients who experi-
enced an event after initial treatment contributed
patient-months of follow-up data to both periods of
the analysis, while patients who did not experience an
event contributed patient-months of follow-up to the
pre-event period only. Since patients were diagnosed
with initial breast cancer and/or the event at different
points in time, there was variation in the follow-up
periods for which individuals contributed data during
each phase of the analysis. Many of the patients died
before the last day for which Medicare data were
available; those surviving past the last day were cen-
sored at the end of follow-up.
Average per-patient cumulative total costs of care
among patients experiencing a breast cancer event
and those without an event were estimated using the
Kaplan–Meier Sample Average (KMSA) estimator
described by Lin et al. [11]. This method provides an
unbiased cost estimate for data in which the follow-up
times of study subjects are variable because of death or
censoring. The KMSA estimator minimizes the bias
associated with censored data by dividing the time
period of interest into short intervals and multiplying
the average cost of patients surviving to the start of
each interval by the probability of survival to that
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interval. These products are then summed over all time
intervals to estimate the expected total costs over the
study period. Relevant components of health-care ser-
vices included care received in hospitals, physicians’
ofﬁces, nursing homes, hospices, and in the patients’
homes (i.e., by home health agencies). All cost data
were based on Medicare payments and adjusted to
2004 constant dollars using Health Care Financing
Administration time adjustment factors.
The expected costs attributable to breast cancer
recurrence were calculated by subtracting the total
expected cumulative costs for patients without an event
(i.e., background medical-care costs) from the total
cumulative costs observed in patients after experiencing
an event. A nonparametric bootstrap analysis was per-
formed in which we resampled with replacement from
our eligible population to create 1000 random repli-
cates of the study population [12]. All estimates of
attributable costs were repeated for each of the 1000
replicate samples, reﬂecting both the costs and survival
in each sample as in Blackhouse et al. [13]. Summary
statistics, including means and standard deviations,
were obtained accordingly.
Primary analyses of data included all patients
regardless of estrogen-receptor (ER) status. Subgroup
analyses were conducted among patients whose tumor
status was classiﬁed as ER-positive, ER-negative, or
ER-unknown; in these analyses, background costs of
care were estimated from patients with the same ER
status.
Results
Sample Selection
A total of 47,246 patients with breast cancer were
identiﬁed in the SEER-Medicare database. Table 2 pre-
sents the impact of the application of study inclusion/
exclusion criteria on the sample size; the ﬁnal number
of patients in the study sample was 10,798, including
7083 women whose tumors were ER-positive, 1339
whose tumors were ER-negative, and 2376 whose ER
status was unknown.
Breast Cancer Events
Breast cancer events were identiﬁed in 2674 patients
(25% of the study sample). Among these individuals,
the type of event was distinguishable in 1833, the
majority of which were local recurrence (n = 958), fol-
lowed by distant recurrence (n = 622), and contralat-
eral primary cancer (n = 253). Differences in type of
event were small in patients with ER-positive (local
recurrence: n = 598, 52%; distant recurrence: n = 381,
33%; contralateral primary: n = 168, 15%), ER-
negative (local recurrence: n = 199, 57%; distant
recurrence: n = 124, 36%; contralateral primary:
n = 25, 7%), and ER-unknown tumors (local recur-
rence: n = 161, 48%; distant recurrence: n = 117,
35%; contralateral primary: n = 60, 18%).
Patient Characteristics
Table 3 contrasts the demographic and clinical charac-
teristics of patients who had breast cancer recurrence
with those who did not. Patients who experienced
contralateral cancerwere somewhat older on average at
the time of the event compared to patients who did not
experience an event andwere less likely to have received
radiotherapy as part of their primary cancer treatment.
These characteristics were similar by ER status.
Postevent Survival
Estimates of 10-year survival after breast cancer events
are shown in Figure 1. The median survival time was
approximately 36 months for patients with local recur-
rence and 8 months for distant recurrence; 53% of
patients with contralateral primary cancer remained
alive after all patients in this group were censored at
97 months. Median survival times were longer for
patients with local recurrence within the ER-positive
(42 months) and ER-unknown (48 months) subgroups
and shorter for patients with ER-negative tumors
(24 months). Survival following distant recurrence
and contralateral primary cancer was similar among
ER-positive (distant recurrence: 9 months; contralat-
eral primary: 96 months), ER-negative (distant recur-
rence: 7 months; contralateral primary: 57% alive at
end point), and ER-unknown patients (distant recur-
rence: 6 months; contralateral primary: 60% alive at
end point).
Costs of Breast Cancer Events
Figure 2 plots cumulative expected total costs following
local and distant recurrence and contralateral primary
cancer over 10 years and contrasts these to background
costs among patients with no recurrence. Costs after
Table 2 Step-by-step implementation of study exclusion crite-
ria and resulting effects on sample size
Exclusion criteria
Number
excluded N
Starting sample size — 47,246
Male sex 334 46,912
Aged less than 65 years at time of diagnosis 15,884 31,028
Not covered by both parts A and B of Medicare
throughout the study period
5,160 25,868
Stage 0 cancer or unknown stage at time of
diagnosis
7,584 18,284
History of any other cancer before diagnosis of
breast cancer
1,175 17,109
Enrolled in Medicare HMO at anytime during the
study period
4,216 12,893
Medicare eligibility on the basis of disability or
end-stage renal disease
569 12,324
Cancer was identiﬁed at the time of death or
autopsy
5 12,319
Initial treatment for breast cancer could not
be identiﬁed in the Medicare claims
1,521 10,798
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distant recurrence accumulate and level off more
rapidly than those after local or contralateral recur-
rence, reﬂecting differences in intensity of acute treat-
ment and postevent survival. Total expected cumulative
costs for distant recurrence, local recurrence, contralat-
eral primary cancer, and no recurrence were $53,454,
$61,601, $61,188, and $42,005, respectively.
Table 4 compares expected 10-year per-patient
costs, from 1000 bootstrapped samples of the origi-
nal data, attributable to each type of breast cancer
event (i.e., net of background costs among patients
with no recurrence) on an undiscounted basis and
discounted at 3% and 5% per annum. Because
patients with local and distant recurrences have
shorter survival than patients without recurrence, the
incremental cost per patient attributable to recur-
rence is positive at ﬁrst and then turns negative in
later years. This is seen in Figure 2 as the cumulative
per-patient costs following distant or local recurrence
diverge from the no recurrence background costs for
several years, but then converge in later years. As a
consequence, discounting has a seemingly counterin-
tuitive effect on 10-year costs attributable to these
types of recurrence—causing them to increase rather
than decrease. Overall, costs attributable to local
recurrence and contralateral breast cancer were
somewhat higher for patients with ER-positive versus
ER-negative or ER-unknown tumors, while ER-
negative patients had the highest costs attributable to
distant recurrence.
Table 3 Characteristics of patients experiencing versus not experiencing selected breast cancer events
Characteristic
Local
recurrence
Distant
recurrence
Contralateral
cancer
No breast
cancer event
n 958 622 253 8,124
Mean age (year) 76.0 76.6 77.4 76.0
Race (%)
Caucasian, non-Hispanic 90.8 90.5 94.1 91.7
Black, non-Hispanic 4.7 6.4 2.8 4.3
Hispanic 0.8 0.2 1.2 0.8
Asian 1.0 1.0 1.2 1.2
Other 2.6 1.9 0.8 2.1
Geographic region (%)
Midwest 28.8 36.3 35.2 35.7
Northeast 18.9 14.6 15.4 15.2
South 6.8 7.4 4.7 5.7
West 45.5 41.6 44.7 43.4
Mean household income ($) 38,013 36,318 37,091 36,195
Primary cancer treatment (%)
Surgery 99.8 99.5 100.0 99.8
Radiotherapy 35.7 30.5 28.1 23.0
Year of diagnosis (%)
1991 33.4 31.5 35.6 31.7
1992 34.8 32.6 33.2 35.9
1993 31.8 35.9 31.2 32.4
In 841 patients the type of recurrence could not be identiﬁed.
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Figure 1 Kaplan–Meier survival curves over
10 years, by type of breast cancer event.
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Discussion
We used data from the SEER-Medicare database to
examine the 10-year impact of breast cancer recur-
rence on survival and medical-care costs. For all cases
of nonmetastatic breast cancer in SEER diagnosed
during calendar years 1991–1993, we utilized infor-
mation contained in SEER records and on Medicare
administrative claims to identify instances of breast
cancer recurrence through 2002, and to assess patterns
of survival and medical-care cost by type of event
(local or distant recurrence, contralateral breast
cancer). Statistical techniques for the analysis of cen-
sored data were used in analyses of both survival and
costs, permitting us to construct 10-year estimates
from the data even though most patients did not have
a full 10-year follow-up.
Our analyses conﬁrm that survival following breast
cancer events varies widely depending on the type of
event, as few patients (7%) with distant recurrence in
our sample survived 10 years compared to approxima-
tely one quarter (27%) of patients with local recurrence
and about one half (53%) of patients with contralateral
breast cancer. The 10-year medical-care costs attribut-
able to breast cancer (i.e., net of background costs) were
highest for patients with contralateral breast cancer
($20,198), followed by local ($18,515) and then distant
($7642) recurrence. The relatively low cost estimated
for distant recurrence was driven primarily by its high
mortality rate, as patients with distant recurrence gen-
erally did not live long enough to incur medical-care
costs throughout the 10-year period. Indeed, rankings
of cumulative medical-care costs throughout the ﬁrst
4 years after recurrence were reversed, with distant
recurrence being the most costly and contralateral
recurrence the least. Only minor differences in survival
and costs post event were observed according to ER
status. Costs were slightly higher among ER-positive
patients, who generally have a better prognosis, live
longer, and therefore incur more costs.
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Figure 2 Expected cumulative costs of care
over 10 years among patients experiencing
selected breast cancer events versus no breast
cancer event.
Table 4 Expected 10-year costs ($) attributable to selected breast cancer events, by type of event and ER status
Discount rate/type of
recurrence
Mean costs (SE)
All patients ER-positive ER-negative ER-unknown
Undiscounted
Distant recurrence 7,642 (2,231) 9,922 (2,908) 13,081 (4,747) 2,518 (4,870)
Local recurrence 18,515 (1,955) 20,083 (2,444) 17,348 (4,536) 18,162 (4,674)
Contralateral cancer 20,198 (4,812) 22,179 (6,699) 12,258 (8,658) 16,854 (7,586)
3% per annum
Distant recurrence 11,450 (2,056) 13,627 (2,711) 15,351 (4,224) 6,769 (4,375)
Local recurrence 19,596 (1,754) 20,879 (2,200) 18,542 (4,012) 19,671 (4,256)
Contralateral cancer 19,183 (4,131) 20,839 (5,732) 12,435 (7,631) 16,578 (6,561)
5% per annum
Distant recurrence 13,579 (1,961) 15,690 (2,606) 16,643 (3,954) 9,160 (4,112)
Local recurrence 20,149 (1,644) 21,267 (2,067) 19,176 (3,725) 20,452 (4,019)
Contralateral cancer 18,575 (3,757) 20,033 (5,201) 12,515 (7,041) 16,416 (6,023)
ER, estrogen-receptor; SE, standard error.
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Our estimates of the 10-year costs of breast cancer
recurrence are reported on a per-patient basis, and
therefore do not shed light on the aggregate cost
burden imposed on the US health-care system. Never-
theless, we can combine our data with other sources to
gain an initial impression of how large this burden
might be. Our analyses suggest that each case of breast
cancer recurrence (excluding contralateral breast
cancer) costs $16,389 on average (net of background
medical-care costs, weighted by type of recurrence,
discounted at 3% annually). Although we are aware of
no data source for the numbers of cases of recurrence
occurring annually in the United States, the National
Cancer Institute estimated that approximately 2.3
million women with a history of breast cancer were
alive in January 2002 [14]. Annual hazard rates of
breast cancer recurrence in each of 12 years after
initial diagnosis have been reported to range from
2.1% to 13.3% [2]. If we assume that two million US
women with a history of breast cancer are at risk of
recurrence, and that the annual recurrence rate is at the
midpoint of the reported range (i.e., 8%), then the
aggregate medical-care cost burden of recurrence in
the United States may range upwards of three billion
dollars annually.
Our data may be used as parameter inputs in eco-
nomic evaluations of breast cancer treatments, such as
adjuvant hormonal therapy with tamoxifen, the aro-
matase inhibitors, or trastuzumab. Economic analyses
of such interventions require estimates of the costs of
all cases of breast cancer recurrence averted, which
constitute a key economic beneﬁt and partial offset to
the costs of adjuvant therapy. Although, to the best
of our knowledge, no study conducted to date has
reported the costs of breast cancer recurrence, the
absence of these data has not stiﬂed the growth of
pharmacoeconomic evaluations in this area [15–18]. A
cursory review of recent cost-effectiveness analyses
highlights the variation in costing methods that have
been employed. Some have been based on patient
surveys and chart review [15], others on physician
surveys and/or expert opinion [16,18], and still others
on retrospective database analysis [17]. The availabil-
ity of national estimates of the costs of breast cancer
recurrence from a reliable data source like SEER-
Medicare may lend some consistency to economic
evaluations of treatment strategies.
This study has several limitations, particularly with
respect to the use of Medicare claims in identifying
recurrence and estimating costs. Although SEER data
are collected for scientiﬁc purposes, Medicare claims
data are comprised of administrative records submit-
ted by providers for the purpose of obtaining reim-
bursement for services provided to Medicare-eligible
patients. Research is not the intended purpose of infor-
mation collected from these claims [19]. We relied on a
combination of ICD-9-CM diagnosis codes and proce-
dure codes to identify breast cancer events and to
classify by type. Our algorithm was developed based
on a previous SEER-Medicare study examining cancer
relapse in acute myelogenous leukemia patients [8]. In
that study, the sensitivity and speciﬁcity of the best
algorithm for detecting recurrence were 86% and
91%, respectively. Because validation of our case-
ﬁnding algorithms was beyond the scope of our study,
our accuracy in identifying patients with breast cancer
recurrence is unknown. A further limitation of our
study is that it is limited to nondisabled Medicare
recipients, who are 65 years of age or older. It is
unknown whether costs following, or attributable to,
breast cancer events are comparable among younger
patients.
The use of Medicare claims to estimate health-care
cost is limited to what Medicare covers for the services
utilized by eligible patients. During the study period,
Medicare did not cover prescriptions for self-
administered medications, an important component of
costs. As a result, our cost estimates do not include
adjuvant breast cancer therapies such as tamoxifen or
aromatase inhibitors. Additionally, our estimates do
not include the costs of prescription drugs commonly
used to treat cancer pain, chemotherapy-induced
nausea, and opportunistic infections. Finally, an
administrative database containing Medicare claims
cannot be used to reliably identify all instances of
recurrence attributable to a patient’s initial breast
cancer using procedure and diagnosis codes. There-
fore, we deﬁned the costs attributable to subsequent
breast cancer events as the difference in costs between
patients with the event compared to background costs
of care among patients without an event (i.e., whose
breast cancer was in remission). Note that patients
who did experience an event differed from those who
did not with respect to age and other characteristics.
We did not control for differences in patient character-
istics, as the KMSA estimator is not generally ame-
nable to inclusion of covariates and Cox regression
techniques for use with censored cost data may
produce biased estimates [20].
With advances in detection and treatment, breast
cancer mortality has declined and attention has turned
in recent years to preventing disease-related events
after primary treatment. Our analyses offer insight into
the magnitude of medical-care costs attributable to
breast cancer recurrence over 10 years and may be
useful in estimating the economic beneﬁts of preven-
tion strategies. This study accordingly may be of inter-
est to clinicians, health economists, policymakers, and
others interested in the economics of breast cancer
recurrence in the United States.
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